Skip to Content

Samsung Biologics/Human Genome

M/26/007

Completed

Transaction details

The proposed acquisition by Samsung Biologics America, Inc., a subsidiary of Samsung Biologics Co., Ltd. of sole control of Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline Holdings (Americas) Inc., has been cleared by the Competition and Consumer Protection Commission.
Case details
  • Notification date:28 January 2026
  • Publication date:28 January 2026
  • Economic sector:Manufacturing - C
  • Economic sub-sector:Manufacture of pharmaceuticals - C.21
  • Simplified merger:Yes
  • Outcome:Cleared
Documents
M.26.007 DeterminationPDF | 343 KB
Timetable

Phase One

  • Wednesday, 28 January, 2026 Notification received
  • Wednesday, 11 February, 2026 Third party submission deadline
  • Thursday, 12 February, 2026 Determination issued
Parties Involved

Samsung Biologics America, Inc.

Samsung Biologics America, Inc. is a subsidiary of Samsung Biologics Co., Ltd which is a company incorporated under the laws of the Republic of Korea and is engaged in biopharmaceutical manufacturing. Samsung Biologics Co., Ltd is a fully-integrated contract development and manufacturing organisation delivering end-to-end biologics to biotechnology and pharmaceutical companies.

Samsung Biologics Co., Ltd is part of the Samsung conglomerate and it's shareholders include Samsung C&T Corporation and Samsung Electronics Co. Limited. Samsung is a conglomerate active in a wide array of industries, including electronics, shipbuilding, engineering and insurance.

 

Human Genome Sciences, Inc

Human Genome Sciences, Inc. is a indirectly wholly owned subsidiary of GSK plc (formerly GlaxoSmithKline). Human Genome Sciences, Inc. is a biopharmaceutical company that manufactures bulk drug substance products.

Human Genome Sciences, Inc. operates two manufacturing plants in Maryland, the United States.

Contacts
View all mergers

Sign up for the latest news from CCPC